TORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company’s pre-IND IL-32 chronic kidney disease (“CKD”) program. The U.S.-based lab was selected for its core competencies in the areas required to support the IL-32 program. It will perform studies on behalf of Arch to generate proprietary data and support the Company’s patent portfolio covering its IL-32 drug candidates and related method-of-use claims. These studies represent the next stage of ...

TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the 2026 American Diabetes Association Thought Leadership Series at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films. The Thought Leadership Film Series is a curated set of films profiling organizations active in research and innovation across the field. The series is designed to increase visibility for groups ...

TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS). Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada. Patient recruitment into the trial is ongoing at Toronto General ...